Josiah Brown, MD
Interventional Cardiology · Anchorage, AKNPI 1043643430
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,306 of the $14,736 with a category attached, or 76.7%. 12 manufacturers reported payments, led by Edwards Lifesciences at 46.7% of the total. Reporting peaked in 2024 at $6,028 and has fallen 53.7% since, to $2,792 in 2025.
Across 229 payments — averaging $64.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$7K
- Boston Scientific$3K
- Medtronic$2K
- Abbott$2K
- Shockwave Medical, Inc$869
- Abiomed$296
- plus $343 from 6 others
What the payments were for
- Grants$1251%
- Travel & lodging$3,30622%
- Food & beverage$11,30677%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 149 | $6,877 |
| Boston Scientific | 30 | $2,643 |
| Medtronic | 18 | $1,903 |
| Abbott | 13 | $1,806 |
| Shockwave Medical, Inc | 7 | $869 |
| Abiomed | 3 | $296 |
| Cleerly, Inc. | 2 | $121 |
| Heartflow, Inc. | 1 | $95 |
| Amgen | 2 | $52 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| Merck | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$1,311
- TRICLIP$1,296
- SAPIEN 3 Ultra RESILIA$1,120
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$626
- PASCAL$572
- Impella$283
- PORTICO$192
- EVOQUE$171
- WATCHMAN FLX$162
How this compares
Too few interventional cardiology providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 39 | $520 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Anchorage
- Jasleen TiwanaAnchorage$5K
- Carson WebbAnchorage$4K
- Thomas KramerAnchorage$2K
- Richard AnschuetzAnchorage$1K
- Blake CharltonAnchorage$1K
- Lee PiersonAnchorage$1K
- Romel WrennFairbanks$22K
- David LemonsPalmer$7K
- Ryan McDonoughPalmer$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.